See the DrugPatentWatch profile for lurbinectedin

There is limited information available on the risks of taking lurbinectedin during pregnancy, as human studies have not been conducted, and the data from animal studies is not conclusive for humans [1]. Lurbinectedin is a type of antineoplastic agent, which is a class of drugs often associated with potential developmental toxicity [1].

Animal studies have shown evidence of developmental toxicity, including embryo-fetal lethality and growth retardation, at maternal exposure levels that were toxic to the mother [1]. However, it is important to note that animal studies do not always predict the way humans will respond [1].

The U.S. Food and Drug Administration (FDA) has classified lurbinectedin as a pregnancy category D drug, which means there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans [2].

In summary, based on the available information, there are potential risks associated with taking lurbinectedin during pregnancy, including developmental toxicity and fetal harm. However, more research is needed to fully understand these risks. As with any medication, it is important to discuss the potential risks and benefits with a healthcare provider before use [1][2].

Sources:
[1] DrugPatentWatch.com, "Lurbinectedin - Side Effects, Dosage, Interactions, and Warnings", <https://www.drugpatentwatch.com/drugs/lurbinectedin>
[2] U.S. Food and Drug Administration (FDA), "Pregnancy Categories", <https://www.fda.gov/media/73132/download>